Development of Bispecific Antibody Targeting Human IL-17A and IL-6
Antibodies · 30.03.2026 · 15 (2) · 29
DOI: 10.3390/antib15020029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibodies, online erschienen am 30.03.2026. Verfasst von Beata Pamuła und 13 weiteren Autor:innen. Beteiligte Einrichtung: Preclinical Development Department, Celon Pharma S.A., Ul. Marymoncka 15, 05-152 Kazuń Nowy, Poland. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Centre of Research and Development; Celon Pharma, National Centre for Research and Development, Ministry of Science and Higher Education of Poland.
Abstract (Originalsprache)
Background/Objectives: Antibodies are a rapidly expanding field in drug discovery, but their monospecificity limits therapeutic applications, particularly in complex inflammatory diseases. Multispecific therapeutics, which combine variable regions targeting two or more antigens, offer potential advantages such as enhanced efficacy, broader target modulation, and reduced side effects. This study aimed to identify and characterize bispecific, VHH-based antibodies simultaneously targeting IL-6 and IL-17A—two key cytokines involved in autoimmune and chronic inflammatory conditions.
Methods
A phage display screening was conducted using llama-derived VHH libraries to select binders against human IL-6 and IL-17A. Binding affinities of individual VHHs and assembled bispecific constructs were assessed using Bio-Layer Interferometry (BLI). Functional activity was evaluated using reporter cell lines responsive to IL-6 and IL-17A signaling. Biophysical and quality assessments of selected VHHs and bispecific antibodies were performed using the Uncle screening platform and LabChip capillary electrophoresis.
Results
Several high-affinity VHH binders were identified for both IL-6 and IL-17A, and incorporated into bispecific antibody formats. The bispecific candidates exhibited simultaneous inhibition of both cytokine pathways in functional reporter assays. Biophysical characterization confirmed good stability and purity profiles for selected molecules.
Conclusions
This study demonstrates the feasibility of generating stable, functional bispecific VHH-based antibodies targeting IL-6 and IL-17A. These constructs show potential as therapeutic agents for treating autoimmune and chronic inflammatory diseases by modulating multiple signaling pathways simultaneously.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Preclinical Development Department, Celon Pharma S.A., Ul. Marymoncka 15, 05-152 Kazuń Nowy, Poland.
- Department of Cell Cultures and Genomic Analysis, Faculty of Medicine, Medical University of Lodz, Ul. Żeligowskiego 7/9, 90-752 Łódź, Poland.
Förderung
- National Centre of Research and Development; Celon Pharma
- National Centre for Research and Development
- Ministry of Science and Higher Education of Poland
Zitieren
APA
Pamuła, B., Banach, M., Mikońska, M., Korytkowska, K., Lacek, K., Śniadała, O., Marczak, M., Flis, K., Sowińska, A., Kołakowski, D., Pieczykolan, J., Zygmunt, B., Wieczorek, M., & Abramczyk, O. (2026). Development of Bispecific Antibody Targeting Human IL-17A and IL-6. Antibodies, 15(2), 29. https://doi.org/10.3390/antib15020029
Vancouver
Pamuła B, Banach M, Mikońska M, Korytkowska K, Lacek K, Śniadała O, et al. Development of Bispecific Antibody Targeting Human IL-17A and IL-6. Antibodies. 2026;15(2):29. doi:10.3390/antib15020029
BibTeX
@article{Pamua2026,
author = {Pamuła, Beata and Banach, Martyna and Mikońska, Marta and Korytkowska, Karolina and Lacek, Krzysztof and Śniadała, Oliwia and Marczak, Małgorzata and Flis, Krzysztof and Sowińska, Aleksandra and Kołakowski, Damian and Pieczykolan, Jerzy and Zygmunt, Beata and Wieczorek, Maciej and Abramczyk, Olga},
title = {Development of Bispecific Antibody Targeting Human IL-17A and IL-6},
journal = {Antibodies},
year = {2026},
volume = {15},
number = {2},
pages = {29},
doi = {10.3390/antib15020029}
}
EUVIMED